Barcelona, 4 July 2018: Despite dramatic uptake in the numbers of women electing to freeze their eggs as insurance against an anticipated age-related fertility decline, there is still little that clinics can predict about outcome based on real-life experience. Indeed, at one of Europe's biggest fertility centres - the Brussels Centre for Reproductive Medicine in Belgium - only 7.6% of women have returned to thaw their eggs and try for a pregnancy. And only one-third of those have been successful.
Details of the follow-up, which recorded the experience of 563 women freezing their eggs between January 2009 and November 2017, are presented as a poster here at the 34th Annual Meeting of ESHRE in Barcelona. Such details, said investigator Michel De Vos from the Brussels group, "are needed for a comprehensive appraisal of social freezing". Otherwise, he added, "little is known about these 'social freezers' and their reproductive outcomes."
The review of data showed that the 563 women in the series had 902 assisted reproduction treatments to collect eggs. And that:
- the mean age of those freezing their eggs was 36.5 years
- a mean number of 8.5 eggs per patient were collected and frozen (by the rapid freezing technique of vitrification) at each treatment cycle
- so far, just 12.8% (72 of 563) have returned to the clinic for reproduction treatment; of these, no more than 43 had their eggs thawed, fertilised and transferred
- of these social freezers 43% had fertilisation with donor sperm either by intrauterine insemination or ICSI
- the overall survival rate of thawed eggs was 73.4%, reflecting the high efficiency of the vitrification technology
- in total the ongoing pregnancy after embryo transfer was 32.6% (14/43)
De Vos also noted that the majority of the social freezers who did return had found a suitable partner to pursue motherhood. But from the data he was unable to clarify "whether their previous decision to undergo oocyte cryopreservation has enhanced the probability of a live birth".
De Vos reported that these results in Brussels are in line with others from large fertility centres, of which one (in Valencia) recorded an ongoing pregnancy rate of 21%, and reflect the limitations of social egg freezing for women freezing eggs after the age of 35. He added that the average number of eggs retrieved in social freezers who did have an ongoing pregnancy was 9.2 eggs per patient.
While social egg freezing in Brussels reflects an upward trend in popularity apparent in many other large European and US fertility centres, De Vos urged women considering uptake after the age of 35 "not to have unrealistic expectations". "Our results show that one in three women who return to the clinic do achieve an ongoing pregnancy with their vitrified oocytes," said De Vos. "They returned at a mean age of 42 years after having their oocytes vitrified at a mean age of 36 years." But he warned that - as with any fertility treatment - egg quality declines markedly with age, and success rates will be lower than 33% in women freezing their eggs beyond this age.
Follow-up of elective oocyte cryopreservation for age-related reasons: utilisation of vitrified oocytes and reproductive outcomes of women who return.
1. The uptake of elective oocyte cryopreservation - also known as social egg freezing - has escalated in the last few years because of the fast freezing technology of vitrification. Not only has vitrification improved the efficiency of embryo freezing but for the first time allowed the viable freezing of eggs. Before then, egg freezing by the conventional slow-freezing method caused damage to the microstructure of the egg from the formation of ice crystals; vitrification reduces cells to a glass-like state in just a few seconds and thereby avoids for formation of ice.
2. While still not universally acknowledged as a public health fact, women are now more aware of their biological clock and the decline in fertility which comes with advancing age. This decline generally begins after the age of 35, and continues to the menopause. Egg freezing as an effective technology thus provides a reasonable insurance against this age-related decline. This is yet another example of an "infertility" treatment being applied in women who are not strictly infertile.
* When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.
For further information on the details of this press release, contact:
Christine Bauquis at ESHRE
Mobile: +32 (0)499 25 80 46